1. Hammerl, D., Rieder, D., Martens, J. W. M., Trajanoski, Z. & Debets, R. Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies. Trends Immunol. 39, 921–936 (2018).
2. Rapoport, A. P. et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914–921 (2015).
3. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
4. Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).
5. Georgiadis, C. et al. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects. Mol. Ther. 26, 1215–1227 (2018).
6. Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255–2266 (2017).
7. Choi, B. D. et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. Journal for ImmunoTherapy of Cancer 7, 1–8 (2019).
8. Cornelissen, J. J. et al. Early CD4+ T-cell effector alloreactivity towards multiple mismatched HLA class II alleles is associated with graft predominance after double umbilical cord blood transplantation (DUCBT). Blood 126, 387 (2015).
9. Nianias, A. et al. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges. Curr Hematol Malig Rep. 14, 261–268 (2019).
10. Nishimura, T. et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12, 114–126 (2013).
11. Vizcardo, R. et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8 + T cells. Cell Stem Cell 12, 31–36 (2013).
12. Kitayama, S. et al. Cellular Adjuvant Properties, Direct Cytotoxicity of Re- differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells. Stem Cell Reports 6, 213–227 (2016).
13. Ueda, N. et al. Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response. Stem cell reports 10, 1935–1946 (2018).
14. Ando, M. et al. A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. Stem Cell Reports 5, 597–608 (2015).
15. Minagawa, A. et al. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell 23, 850-858.e4 (2018).
16. Themeli, M. et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928–933 (2013).
17. Torikai, H. et al. Toward eliminating HLA class i expression to generate universal cells from allogeneic donors. Blood 122, 1341–1349 (2013).
18. Chen, H. et al. Functional disruption of human leukocyte antigen II in human embryonic stem cell. Biol. Res. 48, 1–9 (2015).
19. Rong, Z. et al. An effective approach to prevent immune rejection of human ESC- derived allografts. Cell Stem Cell 14, 121–130 (2014).
20. Gornalusse, G. G. et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat. Biotechnol. 35, 765–772 (2017).
21. Mattapally, S. et al. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy. J. Am. Heart Assoc. 7, e010239 (2018).
22. Han, X. et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc. Natl. Acad. Sci. 116, 10441–10446 (2019).
23. Marino, J., Paster, J. & Benichou, G. Allorecognition by T lymphocytes and allograft rejection. Front. Immunol. 7, 1–9 (2016).
24. Gussow, D., Rein, R., Kottman, A. & Ploegh, H. L. The human beta 2-microglobulin gene . Primary structure and definition of the transcriptional unit. J. Immunol. 139, 3132-3138 (2016).
25. Holling, T. M., Schooten, E. & Van Den Elsen, P. J. Function and regulation of MHC class II molecules in T-lymphocytes: Of mice and men. Hum. Immunol. 65, 282–290 (2004).
26. Salgado, F. J. et al. Interleukin-dependent modulation of HLA-DR expression on CD4 and CD8 activated T cells. Immunol. Cell Biol. 80, 138–147 (2002).
27. Lanier, L. L. NK CELL RECOGNITION. Annu. Rev. Immunol 23, 225–74 (2005).
28. King, A. et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur. J. Immunol. 30, 1623–1631 (2000).
29. Marín, R. et al. Analysis of HLA-E expression in human tumors. Immunogenetics 54, 767–775 (2003).
30. Tomasec, P. et al. Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40. Science. 287, 1031–1033 (2000).
31. Crew, M. D., Cannon, M. J., Phanavanh, B. & Garcia-Borges, C. N. An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells. Mol. Immunol. 42, 1205–1214 (2005).
32. Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795–799 (1998).
33. A.T., B. et al. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 115, 2686–2694 (2010).
34. Cerboni, C. et al. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 110, 606–615 (2007).
35. Ardolino, M. et al. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: Relevance for NK- T cell interaction. Blood 117, 4778–4786 (2011).
36. Tomasec, P. et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat. Immunol. 6, 181-188 (2005).
37. Kruse, V. et al. Human induced pluripotent stem cells are targets for allogeneic and autologous natural killer (NK) cells and killing is partly mediated by the activating NK receptor DNAM-1. PLoS One 10, 1–27 (2015).
38. Yaguchi, T. et al. Human PBMC-transferred murine MHC class I / II-deficient NOG mice enable long-term evaluation of human immune responses. Cellular & Molecular Immunology 15, 953–962 (2018).
39. Ashizawa, T. et al. Antitumor Effect of Programmed Death-1 ( PD-1 ) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin. Cancer Res. 23, 149–158 (2017).
40. Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492-500 (2015).
41. Deuse, T. et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat. Biotechnol. 37, 252–258 (2019).
42. Xu, H. et al. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell 24, 566-578.e7 (2019).
43. Ren, J., Zhang, X., Liu, X., Fang, C. & Jiang, S. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 8, 17002–17011 (2017).
44. Merkle, F. T. et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 545, 229-233 (2017).
45. Okita, K. et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409–412 (2011).
46. Lee, S. et al. Repurposing the Cord Blood Bank for Haplobanking of HLA-Homozygous iPSCs and Their Usefulness to Multiple Populations. Stem Cells 36, 1552–1566 (2018).
47. Kaneko, S. & Yamanaka, S. To be immunogenic, or not to be: That’s the iPSC question. Cell Stem Cell 12, 385–386 (2013).
48. Taylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A. & Bolton, E. M. Generating an iPSC Bank for HLA-Matched Tissue Transplantation Based on Known Donor and Recipient HLA Types. Cell Stem Cell 11, 147–152 (2012).
49. Ichise, H. et al. NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA- Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs. Stem cell reports 9, 853–867 (2017).
50. Wu, X., Zhang, Y., Li, Y. & Schmidt-wolf, I. G. H. Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding. cancers. 12, 1818 (2020).
51. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp : an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 17, 884–890 (2018).
論文の公開元へ
